Optimizing the treatment sequence: the cumulative clinical benefit of treatment initiation with deucravacitinib versus apremilast over 52 weeks in patients with moderate to severe plaque psoriasis from the POETYK PSO-1 trial. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 6, n. 6, p. s62, 2022. DOI: 10.25251/skin.6.supp.62. Disponível em: https://skin.dermsquared.com/skin/article/view/1817. Acesso em: 6 oct. 2025.